About Par Pharmaceutical Companies (NYSE:PRX)
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:PRX
CUSIPN/A
Phone+1-845-5735500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Par Pharmaceutical Companies (NYSE:PRX) Frequently Asked Questions
What is Par Pharmaceutical Companies' stock symbol?
Par Pharmaceutical Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRX."
Who are Par Pharmaceutical Companies' key executives?
Par Pharmaceutical Companies' management team includes the folowing people:
- Paul V. Campanelli, Chief Executive Officer (Age 54)
- Michael A. Tropiano, Chief Financial Officer, Executive Vice President (Age 57)
- Terrance John Coughlin, Chief Operating Officer (Age 52)
- Thomas J. Haughey, Chief Administrative Officer, General Counsel (Age 51)
Has Par Pharmaceutical Companies been receiving favorable news coverage?
News headlines about PRX stock have trended positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Par Pharmaceutical Companies earned a news impact score of 0.27 on Accern's scale. They also assigned press coverage about the healthcare company an impact score of 46.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Par Pharmaceutical Companies?
Shares of PRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Par Pharmaceutical Companies?
Par Pharmaceutical Companies' mailing address is 1 Ram Ridge Rd, CHESTNUT RIDGE, NY 10977-6714, United States. The healthcare company can be reached via phone at +1-845-5735500.
MarketBeat Community Rating for Par Pharmaceutical Companies (PRX)
MarketBeat's community ratings are surveys of what our community members think about Par Pharmaceutical Companies and other stocks. Vote "Outperform" if you believe PRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Par Pharmaceutical Companies (NYSE:PRX) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/26/2016 forward)
Par Pharmaceutical Companies (NYSE:PRX) Earnings History and Estimates Chart
Par Pharmaceutical Companies (NYSE PRX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2012 | | $1.10 | $1.62 | | | View | N/A |  |
| 5/8/2012 | | $0.72 | $0.80 | | | View | N/A | |
| 2/28/2012 | | $0.74 | $0.78 | | | View | N/A | |
| 11/2/2011 | | $0.73 | $0.74 | | | View | N/A | |
| 8/3/2011 | | $0.74 | $0.84 | | | View | N/A | |
| 5/5/2011 | | $0.89 | $0.96 | | | View | N/A | |
| 2/24/2011 | | $0.67 | $0.61 | | | View | N/A | |
| 11/3/2010 | Q3 2010 | $0.54 | $0.86 | | | View | N/A | |
| 8/4/2010 | Q2 2010 | $0.58 | $0.71 | | | View | N/A | |
| 5/4/2010 | Q1 2010 | $0.66 | $0.67 | | | View | N/A | |
| 2/24/2010 | Q4 2009 | $0.57 | $0.65 | | | View | N/A | |
| 11/6/2009 | Q3 2009 | $0.49 | $0.77 | | | View | N/A | |
| 8/4/2009 | Q2 2009 | $0.48 | $0.65 | | | View | N/A | |
| 5/6/2009 | Q1 2009 | $0.27 | $0.49 | | | View | N/A | |
| 11/6/2008 | Q3 2008 | $0.09 | $0.26 | | | View | N/A | |
| 8/7/2008 | Q2 2008 | $0.14 | ($0.59) | | | View | N/A | |
| 5/8/2008 | Q1 2008 | $0.15 | $0.17 | | | View | N/A | |
| 2/29/2008 | Q4 2007 | $0.13 | $0.19 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Par Pharmaceutical Companies (NYSE:PRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Par Pharmaceutical Companies (NYSE PRX) Insider Trading and Institutional Ownership History
Par Pharmaceutical Companies (NYSE PRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Par Pharmaceutical Companies (NYSE PRX) News Headlines
| Source: |
|
Par Pharmaceutical Companies (NYSE:PRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Par Pharmaceutical Companies (NYSE:PRX) Income Statement, Balance Sheet and Cash Flow Statement
Par Pharmaceutical Companies (NYSE PRX) Stock Chart for Thursday, April, 26, 2018
Loading chart…
